Dr. Gopal Saha has over 22 years of experience in drug development across a broad range of therapeutic areas such as endocrine, metabolic, nephrology, and oncology. Prior to joining Rezolute, Dr. Saha served as the Vice President of Clinical Development at Apollomics, Inc. and was responsible for proving clinical leadership for the global development of an oral treatment (cMET-inhibitor, TKI) for non-small cell lung cancers, glioblastoma, and other solid tumors due to a rare genetic mutation (cMET alteration). From 2013-2021, Dr. Saha played a key role at FibroGen, Inc. in the development and approval of Roxadustat (Evrenzo®, an oral HIF-PH inhibitor for treatment of renal anemia) in the EU, Japan, and China by providing clinical leadership in Phase 3 programs. Prior to FibroGen, Dr. Saha held a clinical development position at Metabolex, now Cymabay Therapeutics, from 2004 to 2013 where he developed treatments for diabetes, gout and other metabolic disorders. He holds several patents and authors more than 20 publications in the field of endocrine/metabolic, nephrology, hematology, and oncology. 

Dr. Saha earned his medical degree (MBBS) from Chittagong Medical College, Bangladesh in 1987 and he practiced medicine in South Africa before transitioning into drug development in the USA.